

amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meeting:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Clinical Sciences.

*Date:* August 15, 1996.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge 2, Room 4112 (Telephone Conference).

*Contact Person:* Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435-1783.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 12, 1996.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 96-20939 Filed 8-13-96; 1:24 pm]

BILLING CODE 4140-01-M

### Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) (NIH) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 61 FR 36737, July 12, 1996), is amended to reflect the reorganization of the Office of the Director, NIH (OD/NIH) (HNA). The reorganization consists of the following: (1) In the Office of the Director (HNA) establish the Office of Program Coordination (HNAN), Office of Community Liaison (HNAP), Office of Legislative Policy and Analysis (HNAQ) (elevated from the Office of Science Policy and Technology Transfer, Office of Legislative Policy and Analysis [HNA67]), and Executive Office (HNAR). (2) In the Office of Disease Prevention (HNA2) establish the Office of Dietary Supplements (HNA25); the Office of Rare Diseases (HNA26) (transferred intact from the Office of

Science Policy and Technology Transfer, Office of Rare Disease Research [HNA6533]); and the Office for Alternative Medicine (HNA27) (transferred intact from the Office of Science Policy and Technology Transfer, Office for Alternative Medicine [HNA6532]). (3) In the Office of Intramural Research (HNA4) establish the Office of Technology Transfer (HNA46) (transferred intact from the Office of Science Policy and Technology Transfer, Office of Technology Transfer [HNA68]); and establish the Office of Loan Repayment and Scholarship (HNA47). (4) Retitle the Office of Science Policy and Technology Transfer (HNA6) to the Office of Science Policy (OSP) (HNA6); elevate and rename the Recombinant DNA Branch (HNA6534) to the Office of Recombinant DNA Activities (HNA69); rename the Office of Strategic Planning and Evaluation (HNA66) to the Office of Science Policy and Operations Research (HNA66); abolish the Science Policy Studies Center (HNA65); and elevate and rename the Science Education Policy Branch (HNA6535) to Office of Science Education (HNA63).

*Section HN-B, Organization and Functions*, is amended as follows:

(1) Under the heading *Office of the Director (HNA)*, insert the following:

*Office of Program Coordination (HNAN)*. Provides essential support functions for the Office of the Director, including: (1) all Executive Secretariat functions, including correspondence control and tracking; (2) Committee Management functions for all of NIH, which consist of setting policy for all Advisory Committees, Councils, and Boards, providing oversight on reports and other documentation, serving as a liaison with Department committee management staff, and providing technical guidance and information relevant to the operations of advisory bodies; and (3) other primary support functions.

*Office of Community Liaison (HNAP)*.

(1) Advises the Director and the Deputy Director, NIH, on policies, programs, and issues involving the NIH and its community; (2) plans and directs activities to promote collaboration and cooperation between the NIH and its community; (3) conducts and oversees studies, projects, and evaluations designed to address problems, questions, and issues of community concern and environmental impact; (4) ensures that NIH activities that affect the community involve community representation at all levels of design, review, and implementation; and (5) ensures effective communication and collaboration on policy and programs

involving the community between the OD and the operating components of the NIH.

*Office of Legislative Policy and Analysis (HNAQ)*. (1) Advises the NIH Director, Deputy Director, OD staff, and the ICDs on the full range of legislative issues, and provides leadership and direction for NIH legislative analysis, development, and liaison; (2) identifies, analyzes, and reports on legislative developments relevant to NIH programs and activities and the national biomedical research effort; (3) plans and develops new legislative proposals and monitors their progress through the legislative process, including changes in the statutory base of NIH activities; (4) assesses, monitors, and manages the NIH relationship with the NIH Congressional Authorizing and Appropriations Committees and takes necessary action to facilitate improvements in these relationships; (5) provides coordination on NIH legislative matters with the Department, the Congress, Federal Agencies, and other non-Federal national and international organizations; (6) coordinates the preparation of testimony or statements for the OD/NIH before congressional committees or other groups; and (7) develops special reports, staff documents or other studies concerning NIH interests, activities, and relationships.

*Executive Office (HNAR)*. Serves in both a staff and operational capacity for all administrative support activities for the Office of the Director, excluding the Office of Research Services.

(2) Under the heading *Office of the Director (HNA)*, *Office of Disease Prevention (HNA2)*, insert the following:

*Office of Dietary Supplements (HNA25)*. (1) Advises the Associate Director for Disease Prevention and provides guidance to the research institutes on research related to the health benefits of dietary supplements and their role in disease prevention; (2) conducts, promotes, and coordinates research at NIH relating to dietary supplements; (3) collects and compiles the results of scientific research relating to dietary supplements; (4) serves as principal advisor to the Secretary, Department of Health and Human Services and the agencies of the Public Health Service on non-regulatory issues relating to dietary supplements; and (5) compiles and maintains a database of scientific research and funding.

*Office of Rare Diseases (HNA26)*. (1) Guides and coordinates NIH-wide activities involving research into combating and treating the broad array of rare diseases (orphan diseases); (2) manages the NIH Rare Diseases and

Orphan Products Coordinating Committee; (3) develops and maintains a centralized database on rare diseases; (4) coordinates and provides liaison with Federal and non-Federal national and international organizations concerned with rare disease research and orphan products development; (5) advises the OD/NIH on matters relating to NIH-sponsored research activities that involve rare diseases and conditions; and (6) responds to requests for information on highly technical matters and matters of public policy relative to rare diseases and orphan products.

*Office for Alternative Medicine (HNA27).* (1) Advises the OD/NIH on the study of alternative medicine; (2) guides and coordinates the NIH-wide activities involving alternative medicine; (3) responds to requests for information on highly technical matters and matters of public policy relative to alternative medicine; (4) identifies specific research efforts receiving support that are related to the assessment or validation of alternative medicine; and (5) determines the appropriate studies needed to evaluate alternative medicine.

(3) Under the heading *Office of the Director (HNA)*, *Office of Intramural Research (HNA4)*, insert the following:

*Office of Technology Transfer (HNA46).* (1) Develops policy and procedures for NIH, CDC, and FDA to follow for the implementation of Cooperative Research and Development Agreements (CRADAs), patent licenses, and other technology transfers; (2) implements Patent Policy Board decisions and policies; (3) drafts, negotiates, and periodically revises model forms and agreements; (4) provides advice to ICDs on licenses and agreements; (5) develops policy statements on various technology transfer issues; (6) tracks the OTT budget and prepares an annual status report on the OD/NIH; (7) provides coordination and management of the goals, functions, and operations of the Division of Technology Development and Transfer and the Division of Technology Transfer Support; (8) coordinates and provides planning and liaison support for international CRADAs and technology transfers (9) creates and implements special programs relating to technology transfer by State and local governments and universities; (10) drafts and presents congressional testimony, and drafts technology transfer-related responses to other congressional inquiries; (11) provides operational management activities; (12) assists the Office of the General Counsel (OGC) in evaluating

patent-related litigation matters; (13) participates with OGC or independently negotiates settlements or contested matters with licensees or other parties involved with NIH/CDC/FDA in technology transfer or utilization matters; (14) represents the NIH/CDC/FDA in technology transfer or utilization matters; (15) represents the above agencies at a variety of professional conferences and other public fora; (16) investigates special issues; (17) evaluates the need for and develops new programs in technology management and technology transfer for the above agencies; (18) develops licensing strategies for NIH/CDC/FDA intramural and CRADA inventions; (19) negotiates licenses and other technology transfers; (20) works with scientist inventors, contract attorneys, and others in preparing patent applications and prosecuting these applications at the Patent Office level; (21) handles infringements in consultation with the OGC at the Patent Office level; and (22) makes recommendations to the OGC for referral of matters to the Department of Justice.

*Office of Loan Repayment and Scholarship (HNA47).* (1) Advises the Deputy Director for Intramural Research on matters pertaining to the development and management of educational loan repayment/forgiveness programs; (2) administers individual loan repayment contracts; (3) maintains contact and negotiates repayment schedules with educational lenders; (4) provides fiscal oversight for loan repayment funds; (5) formulates and recommends policies on loan repayment programs for intramural and extramural programs; (6) provides staff support to the loan repayment review committees; (7) analyzes applicant eligibility requests and recommends review by loan repayment committees; (8) serves as executive secretary for the loan repayment review committees; (9) performs a variety of activities involving the recruitment of postdoctoral fellows to the intramural research programs, including information dissemination and site-visits; (10) responds to inquiries from the PHS, Federal and private agencies concerning loan repayment program development; (11) administers the undergraduate scholarship program and all activities attendant to the operations of the undergraduate scholarship program; and (12) administers the NRC Research Associates Program.

(4) Under the heading *Office of the Director (HNA)*, *Office of Science Policy and Technology Transfer (HNA6)*, (a) delete the title and substitute the following: *Office of Science Policy*

(HNA6); (b) delete the title of the *Office of Strategic Planning and Evaluation (HNA66)* and substitute *Office of Science Policy and Operations Research (HNA66)*; (c) delete the title and functional statement in their entirety of the *Science Policy Studies Center (HNA65)*, the *Office for Alternative Medicine (HNA6532)*, the *Office of Rare Disease Research (HNA6533)*, the *Recombinant DNA Branch (HNA6534)*, the *Science Education Policy Branch (HNA6535)*, the *Office of Legislative Policy and Analysis (HNA67)*, and the *Office of Technology Transfer (HNA68)*.

(5) Under the heading *Office of the Director (HNA)*, *Office of Science Policy (HNA6)*, insert the following:

*Office of Science Education (HNA63).* Plans, develops, and coordinates a comprehensive science education program to strengthen and enhance efforts of the NIH to attract young people to biomedical and behavioral science careers and to improve science literacy in both adults and children. The Office: (1) develops, supports, and directs new program initiatives at all levels with special emphasis on targeting students in grades K–16, their educators and parents, and the general public; (2) advises NIH leadership on science education issues; (3) examines and evaluates research and emerging trends in science education and literacy for policy-making; (4) works closely with NIH extramural, intramural, women's health, laboratory animal research, and minority program offices on science education special issues and programs to assure coordination of NIH efforts; (5) works with NIH ICDs to enhance communication of science education activities; and (6) works cooperatively with other public and private sector organizations to develop and coordinate activities.

*Office of Recombinant DNA Activities (HNA69).* (1) Develops and implements NIH policies and procedures for the safe conduct of recombinant DNA activities, including human gene therapy; (2) reviews and evaluates the composition of Institutional Biosafety Committees; (3) develops registries of activities related to recombinant DNA research and human gene therapy; (4) coordinates and provides liaison with Federal and non-Federal national and international organizations concerned with recombinant DNA and human gene therapy activities; (5) provides advice to the OD/NIH, other Federal agencies, and State regulatory organizations concerning recombinant research and human gene therapy; and (6) responds to requests for information on highly technical matters and matters of public

policy related to recombinant DNA and human gene therapy activities.

Dated: August 1, 1996.

Harold Varmus,  
Director, NIH.

[FR Doc. 96-20776 Filed 8-14-96; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

### Office of the Assistant Secretary for Housing-Federal Housing Commissioner; Notice of Sale of Single Family Mortgage Loans

[Docket No. FR-4121-N-01]

**AGENCY:** Office of the Assistant Secretary for Housing-Federal Housing Commissioner, (HUD).

**ACTION:** Notice of sale of single family mortgage loans.

**SUMMARY:** This notice announces the Department's intention to sell approximately 17,500 Secretary-held single family mortgage loans (the "loans") in a sealed bid auction. The loans were insured under various sections of the National Housing Act (the Act) and thereafter assigned to the Department pursuant to Section 230 of the Act. The loans are secured by single family properties located nationwide. This notice also describes the bidding process for these loans.

**DATES:** Bid Packages will be available to eligible bidders on or about July 15, 1996. The auction is currently scheduled for September 4, 1996.

**ADDRESSES:** Bid packages will be available from FHA's Financial Advisor, Merrill Lynch & Co. ("Merrill") 250 Vesey St., New York, NY 10281. Bid Packages will be made available only to parties who complete a Confidentiality Agreement and Qualification Statement and are deemed eligible bidders by Merrill. Interested parties can obtain a Confidentiality Agreement and Qualification Statement by calling 1-(800) 363-4704. Merrill will forward Bidding Materials to eligible bidders via overnight courier. Asset files for the loans included in the sale are available for review by eligible bidders who visit the due diligence facility located at 1730 M Street NW., Washington, DC 20036. To schedule a visit to the due diligence facility or to order supplemental information on the loans, eligible bidders should contact Susan Munson at (202) 530-1253. This is not a toll-free number. The due diligence facility will be open between the hours of 8:00 a.m. and 8:00 p.m., Monday through Saturday. The facility will open on or

about July 12, 1996 and will close on or about August 22, 1996. The last telephone number is not a toll-free number.

#### FOR FURTHER INFORMATION CONTACT:

Joseph McCloskey, Director, Single Family Servicing Division, Office of Insured Single Family Housing, Room 9178, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; telephone (202) 708-1672. For hearing or speech-impaired individuals, this number may be accessed via PT (text telephone) by calling the Federal Information Relay Service at 1-800-877-8339 (this is a toll-free number).

**SUPPLEMENTARY INFORMATION:** The Department intends to sell approximately 17,500 Single Family loans in this auction. The loans are secured by single family properties and are performing and non-performing. The loans will be divided into one million dollar loan blocks, which will be further arranged into groups. A list of specific loans and loan block and group descriptions will be contained in the Bid Package. No loans will be sold individually. The loans will be sold without Federal Housing Administration (FHA) insurance. The Department will offer interested parties an opportunity to bid competitively on loan pools which they may create from combinations of loan blocks, subject to conditions set forth in the bid package. The Department shall use its sole discretion to evaluate and determine winning bids.

#### The Bidding Process

These are the essential terms of sale. The Loan Sale Agreement will provide additional details. To ensure a competitive bidding process, the terms of sale are not subject to negotiation.

The Department will describe in detail the procedure for participating in the Single Family Loan Sale in a Bid Package, which will include bid forms, a nonnegotiable loan sale agreement prepared by the Department (Loan Sale Agreement), specific bid instructions, as well as pertinent information on the loans such as total outstanding unpaid principal balances and interest rate ranges, maturity rates, geographic locations and performance. The bid packages also include computer diskettes containing data on all of the mortgage loans.

Bid Packages will be available approximately 6 weeks prior to the Bid Date. The Bid Package will also include instructions for Bidder Registration and will contain procedures for obtaining supplemental information about the

loans. Any interested party may request a copy of the Bid Package by sending a written request together with a duly executed Confidentiality Agreement and Qualification Statement to the address specified in the **ADDRESSES** section, above, of this notice.

Prior to the Bid Date a Bid Package Supplement will be mailed to all eligible bidders. It will contain the final list of loans to be conveyed to the successful bidder(s).

Each bidder must include with its bid a deposit equal to 10% of the amount of its bid(s). If a successful bidder fails to abide by the terms of the Loan Sale Agreement, including paying the Department any remaining sums due pursuant to the Loan Sale Agreement and closing within the time period provided by the Loan Sale Agreement, the Department shall retain and accept any deposit as liquidated damages.

#### Due Diligence Facility

An investor due diligence period will take place prior to the Bid Date. During the investor due diligence period, eligible bidders may, for a non-refundable fee of \$500, review all asset file documents which have been imaged onto a database by visiting the due diligence facility located at 1730 M Street N.W., Washington, D.C. 20036 and/or via modem a *limited number of identified asset files*. Finally, bidders may purchase a CD Rom disc containing substantial due diligence materials such as 36 month payment histories and Brokers' Price Opinions at a cost of \$500.

Specific instructions for ordering information in electronic format or making an appointment to visit the due diligence facility will be included in the Bid Package. The Department reserves the right to charge a reasonable fee to cover its costs in duplicating and forwarding any information requested by an interested party.

#### FHA Reservation of Rights

The Department reserves the right to delete loans from the Loan Sale at any time prior to the bid date for any reason and without prejudice to its right to include any loans in a later sale. The Department also reserves the right to terminate this sale at any time prior to the bid date.

The Department reserves the right to use its sole discretion to evaluate and determine winning bids. The Department reserves the right at its sole discretion and for any reason whatsoever to reject any and all bids.

The Department reserves the right to conduct a "best and final" round among top bidders for loan blocks or pools